Eliminating solid tumors with AI-driven, multiplex gene-edited CAR-T cells
Advancing cell therapies that break through immunosuppressive tumor barriers, enabling effective and durable cancer control
KiraGen Bio is proud to join the 2048 Ventures Biotech Studio, marking a pivotal step in our quest to innovate CAR-T therapies for solid tumors. This recognition fuels our journey with vital resources and expert networks, accelerating our path to transforming cancer treatment.
Our collaboration with BioLM propels the development of our state-of-the-art KiraLOGIC® Machine Learning model with the latest in AI technology. This partnership will accelerate the rational design of our TME-Guarded CAR-T cell therapies, showcasing our commitment to pioneering innovative cancer treatment solutions.
HUCP Innovation Fund x CBE Ventures Competition
Finalists in the 2023 Harvard Undergraduate Capital Partners Innovation Fund x Consulting, Business, the Environment Venture Competition
Nucleate Activator Program
Finalists in the 2024 Nucleate Activator Program final pitch showcase in Boston
Presidents Innovation Challenge
Semi-finalists in the 2024 Harvard iLab's President's Innovation Challenge
Redefining CAR-T with a differentiated approach:
AI-driven design and multiplex gene editing for superior efficacy against solid tumors.
Leveraging machine learning to pinpoint optimal gene editing combinations, enhancing CAR-T cell efficacy against solid tumors.
Multiplex Gene Editing
Employing cutting-edge technology to simultaneously edit 8+ genes, setting a new standard in cell therapy engineering.
Our allogeneic CAR-T cells are engineered to maintain efficacy against immunosuppressive solid tumor microenvironment.
Meet the Team
Aaron Edwards, MSc, MS/MBA ('24)
Aaron Edwards, an MS/MBA Biotechnology candidate at Harvard Business School, has led innovative cell and gene therapy projects across prominent biotech companies. At bluebird bio, he spearheaded early programs developing gene-edited immunotherapies including both CAR-T and TCR-T. He then served as the in vitro biology lead for Beam Therapeutics’ BEAM-201, now a clinical stage asset. His experience also includes driving advancements at Eli Lilly, 1910 Genetics, BioMarin and Rejuvenate Bio. As CEO of KiraGen, Aaron leverages his acute blend of hands-on cell engineering expertise and business acumen to propel the next generation of genetic medicines.
Ryan Murray, PhD ('24)
Ryan Murray, a PhD candidate at Northeastern University, leads innovative research to unlock the potential of CAR-T cell therapy for solid tumors using cutting-edge gene editing. At bluebird bio, he pioneered synthetic biology strategies to enhance engineered T cell products. His significant contributions further include leading early development efforts for Beam’s oncology IND BEAM-201 and spearheading high-impact initiatives like Fifty 50 Bio x Climate and Nucleate. As CSO at KiraGen, Ryan leverages his sharp expertise across key areas in engineered cell therapy to propel the next generation of genetic medicines